SureTrader
Home > Boards > US Listed > Cannabis > Zynerba Pharmaceuticals (ZYNE)

ZYNE upgraded to $17.00. Look for more of these.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
cjstocksup Member Profile
Member Level 
Followed By 2,992
Posts 210,769
Boards Moderated 2
Alias Born 07/30/07
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2018 4:57:38 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2018 2:56:28 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/13/2018 3:52:26 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2018 9:10:20 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/9/2018 1:17:29 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/1/2018 9:41:44 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/30/2018 9:01:37 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/16/2018 4:13:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/16/2018 4:13:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/16/2018 4:13:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/16/2018 4:12:45 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/16/2018 4:12:18 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2018 4:09:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2018 4:08:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/4/2018 8:01:55 AM
Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update GlobeNewswire Inc. - 1/3/2018 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2018 6:06:33 AM
Biotech Market Banking on Big Cannabis Returns NetworkNewsWire - 12/19/2017 8:45:00 AM
Dangerous Opioid Side Effects Shift Market Focus to Cannabis for Chronic Pain NetworkNewsWire - 12/13/2017 8:45:00 AM
Advanced Biosynthesis Setting New Standards for Cannabinoid-based Pain Management NetworkNewsWire - 12/6/2017 8:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/4/2017 7:31:33 AM
Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 ... GlobeNewswire Inc. - 12/3/2017 12:01:00 PM
Zynerba Pharmaceuticals Announces Poster Presentation at the 2017 Annual Meeting of the American Epilepsy Society (AES) GlobeNewswire Inc. - 11/21/2017 9:00:00 AM
Innovation Drives Value for Leading Cannabis Biotechs NetworkNewsWire - 11/15/2017 8:45:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/14/2017 8:03:15 AM
cjstocksup Member Level  Monday, 10/02/17 11:33:43 AM
Re: LittleBird post# 887
Post # of 1048 
ZYNE upgraded to $17.00. Look for more of these.
UPDATE: Cantor Fitzgerald Upgrades Zynerba Pharmaceuticals (ZYNE) to Overweight
October 2, 2017 5:55 AM

(Updated - October 2, 2017 6:54 AM EDT)


(updated to add analyst comment)

Cantor Fitzgerald upgraded Zynerba Pharmaceuticals (NASDAQ: ZYNE) from Neutral to Overweight with a price target of $17.00 (from $4.00).

Analyst Elemer Piros cites the phase 2a data in Fragile X syndrome noting encouragement from the potential for ZYN002 in treating the disease. The analyst sees upside catalysts from additional regulatory clarity on late-stage development which is slated for 2018.

For an analyst ratings summary and ratings history on Zynerba Pharmaceuticals click here. For more ratings news on Zynerba Pharmaceuticals click here.

Shares of Zynerba Pharmaceuticals closed at $8.36 Friday.
https://www.streetinsider.com/dr/news.php?id=13346899&gfv=1


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist